Download this infographic to learn more about how hospitals and health systems support behavioral health in rural communities ...

Matthew Perry, actor best known for playing Chandler Bing on iconic TV show Friends, died of drug overdose exactly a year ago ...

6- the protection of the new use of drug candidates, and finally 7- the clinical evaluation through clinical trials or compassionate prescription procedures. In this article, we explore the field of ...

Could these medications — collectively known as GLP-1 receptor agonists — also fight America’s most difficult drug problems ... people with opioid use disorder and found that those who ...

That thing is disorder. Charles Fain Lehman, a fellow at the Manhattan Institute who studies crime and drug policy, wrote a piece in his newsletter, The Causal Fallacy, about exactly this question.

Oct 17 - The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' (AVDL.O), opens new tab sleep disorder drug for children aged 7 years and older, broadening its use and heating ...

Drugs such as Novo Nordisk’s blockbuster Ozempic can cut drug and alcohol abuse by up ... around 500,000 people with a history of opioid use disorder were analyzed, of which just more than ...

Aaron Kofsky isn’t just a random staffer; he is JD Vance’s financial policy adviser during an election cycle that cares about crypto. If you buy something using links in our stories, we may ...

Pormezz – stock.adobe.com The new study has found that opioid use disorder patients taking a GLP-1 drug like Ozempic had a 40% lower rate of opioid overdose than those without a prescription.

A new study published in the journal Addiction on October 16 investigates whether GLP-1 RAs could prove to be effective treatments for substance use disorders (SUDs). Researchers looked at 100 ...

“Traditionally, substance use disorder treatments focus on addressing the symptoms and physiological effects of substance use directly," Qeadan tells Well+Good. "GLP-1 receptor ...

A newly published study by Akshaya Bhagavathula, NDSU associate professor of epidemiology, highlights the growing disparities in substance use disorders (SUD) mortality in the United States.